Skip to main content
Journal ArticleOPEN ACCESS

Salvage Therapy in Early Relapse of T-Lymphoblastic Leukemia/Lymphoma Using Daratumumab/Nelarabine Combination: Two Consecutive Cases

  • Molle I
  • Petruskevicius I
  • Kamper P
  • et al.
Case Reports in Hematology (2022) 2022 1-3
DOI: 10.1155/2022/9722787
N/ACitations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Treatment of early relapses of T lymphoblastic leukemia/lymphoma is often unsuccessful. We tested an experimental regimen containing daratumumab and nelarabine in two young patients with early relapses of T lymphoblastic lymphoma and T-ALL, respectively. Both patients achieved a deep complete remission. Combining daratumumab with chemotherapy may have a role in relapsing T lymphoblastic leukemia/lymphoma.

Cite

CITATION STYLE

APA

Molle, I., Petruskevicius, I., Kamper, P., & d’Amore, F. (2022). Salvage Therapy in Early Relapse of T-Lymphoblastic Leukemia/Lymphoma Using Daratumumab/Nelarabine Combination: Two Consecutive Cases. Case Reports in Hematology, 2022, 1–3. https://doi.org/10.1155/2022/9722787

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free